IBIS-II study finds anastrozole reduces breast cancer rates for high risk postmenopausal women

(Queen Mary University of London) The Queen Mary University of London professor leading an international breast cancer study says anastrozole -- rather than tamoxifen -- should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.